MIRA Pharmaceuticals Receives Nasdaq Delisting Notice After Stock Falls Below $1
MIRA is trading near its 52-week low of $0.772 (2.6% above the low).
Summary
MIRA Pharmaceuticals received a Nasdaq deficiency letter on July 27, 2026, after its stock traded below $1 for 30 consecutive days. The company has until January 25, 2027, to regain compliance or face delisting.
Key Events · Legal and Risk Events · MIRA
-
Nasdaq Delisting Notice Received
On July 27, 2026, Nasdaq notified MIRA that its stock failed the $1 minimum bid price requirement after 30 consecutive business days below $1, with the closing price at $0.792 as of today.
-
180-Day Compliance Period
The company has until January 25, 2027, to regain compliance by maintaining a closing bid price of at least $1 for ten consecutive business days.
-
Potential Reverse Split to Cure
If the initial 180-day period lapses without compliance, MIRA may qualify for an additional 180 days by committing to a reverse stock split, though success is not guaranteed.
-
Delisting Risk Amid Going Concern
A delisting would remove MIRA from the Nasdaq Capital Market, severely limiting liquidity and capital-raising ability for a company already operating under a going concern warning.
Analysis · MIRA · Life Sciences
MIRA Pharmaceuticals has been formally notified by Nasdaq that its stock no longer meets the $1 minimum bid price requirement, triggering a 180-day compliance period that runs through January 25, 2027. The stock closed at $0.792 today, near its 52-week low, and must trade above $1 for ten consecutive business days to regain compliance. If it fails, the company may seek an additional 180 days by committing to a reverse stock split. A delisting would severely impair liquidity and access to capital for a pre-revenue biotech already operating under a going concern warning. The notice arrives amid a series of positive preclinical and licensing milestones, creating a sharp disconnect between clinical progress and market valuation.
At the time of this filing, MIRA was trading at $0.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $33.3M. The 52-week trading range was $0.77 to $2.45. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.